US20140207105A1 - Methods for Effectively and Rapidly Desensitizing Allergic Patients - Google Patents
Methods for Effectively and Rapidly Desensitizing Allergic Patients Download PDFInfo
- Publication number
- US20140207105A1 US20140207105A1 US14/240,706 US201214240706A US2014207105A1 US 20140207105 A1 US20140207105 A1 US 20140207105A1 US 201214240706 A US201214240706 A US 201214240706A US 2014207105 A1 US2014207105 A1 US 2014207105A1
- Authority
- US
- United States
- Prior art keywords
- antigen
- allergen
- percent
- delivering
- microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/003—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Definitions
- the present invention is generally in the field of compositions to induce tolerance to allergens.
- Allergen immunotherapy also known as allergy shots, is a form of long-term treatment that decreases symptoms for many people with allergic rhinitis, allergic asthma, conjunctivitis (eye allergy) or stinging insect allergy. Allergy shots decrease sensitivity to allergens and often lead to lasting relief of allergy symptoms even after treatment is stopped. This makes it a cost-effective, beneficial treatment approach for many people.
- Allergy shots work like a vaccine.
- the body responds to injected amounts of a particular allergen, given in gradually increasing doses, by developing immunity or tolerance to the allergen by producing immunoglobulin G (“IgG”) instead of IgE.
- IgG immunoglobulin G
- Allergy shots are not used to treat food allergies. The best option for people with food allergies is to strictly avoid that food.
- the effective maintenance dose depends on the level of allergen sensitivity and the response to the build-up phase. During the maintenance phase, there will be longer periods of time between treatments, ranging from two to four weeks. Symptoms may decrease during the build-up phase, but it may take as long as 12 months on the maintenance dose to notice an improvement. If allergy shots are successful, maintenance treatment is generally continued for three to five years. Allergy shots have shown to decrease symptoms of many allergies. It can prevent the development of new allergies, and in children it can prevent the progression of allergic disease from allergic rhinitis to asthma. The effectiveness of allergy shots appears to be related to the length of the treatment program as well as the dose of the allergen. Some people experience lasting relief from allergy symptoms, while others may relapse after discontinuing allergy shots.
- Th2 lymphocytes including interleukins 4, 5, and 13, have been associated with the promotion of IgE and eosinophilic responses in atopy. Berger, BMJ, 321:424.1 (2000). Ways to redirect allergic Th2 responses in favor of Th1 responses should be beneficial in reducing incidences of allergic reactions.
- compositions for delivering antigens to the lymphatic system in doses that desensitize patients to future exposure to antigens have been developed. Rapid desensitization is achieved by introducing small quantities of antigen into the lymphatic system.
- the compositions provide therapeutically effective levels of antigen within the lymph, where macrophages reside in the greatest concentration.
- the compositions can be administered by intradermally, for example, via microneedles or microparticles, orally, for example, via enteric coated capsules or tablets, or by autologous transfusion.
- the methods and compositions for delivering antigens orally achieve uptake by the Peyer's patches of the small intestine.
- a population of macrophages exposed to antigen is isolated in whole or fractionated blood for autologous transfusion into the patient.
- compositions preferably increase immunoglobulin G levels specific to the allergen without significantly increasing the immunoglobulin E levels specific to the allergen.
- the compositions improve allergic desensitization as measured by decreased Th2 response (for example, Th2-type cytokines) and/or increase Th1 responses, for example, Th1-type cytokines.
- FIG. 1 shows Coulter particle sizing data of ovalbumin-chitosan microparticles for allergen desensitization.
- rapid desensitization refers to increasing the tolerance to one or a group of allergens more quickly than in the absence of treatment.
- the term “tolerance” refers to the level of allergic response to a particular quantity of allergen.
- the term “antigen” refers to a substance or substances alone or in combination that when introduced into the lymphatic system induces production of antibodies that bind to a fraction of the molecule or molecules.
- allergen refers to a substance that could cause an allergic reaction in a patient.
- allergic reaction refers to any untoward response to an allergen.
- lymphatic system refers to the network of lymph containing vessels.
- intradermal refers to residing within the dermal layer of skin or between the epidermal and dermal layers.
- microneedle refers to a protrusion capable of penetrating the human epidermis in which its largest axis is less than three millimeters in length.
- harvested microneedle refers to any microneedle that is capable of penetrating the human epidermis.
- microparticle refers to any shaped particle that has at least one dimension less than one millimeter in size.
- autologous transfusion refers to a whole or fractionated blood sample returned to the patient from whom it was taken by injection or intravenous infusion.
- equivalent circle diameter refers to the diameter of a circle having the same cross-sectional area as the object being measured.
- reservoir-type delivery system refers to formulations containing one or multiple antigen-rich and antigen-poor regions within each discrete element of the delivery system.
- matrix-type delivery system refers to formulations containing a random distribution of antigen within each discrete element of the delivery system.
- biodegradable refers to a class of materials that undergo reductions in molecular weight upon introduction into a cell-containing environment.
- bioadhesive refers to a class of materials that adheres to one or more biological substrates.
- adjuvant refers to any agent that increases the immunological response to an antigen.
- tip radius refers to the radius of a circle equivalent in cross-sectional area to the smallest aspect of a microstructure.
- micropillar refers to any microstructure that is longer than it is wide and mechanically supports another microstructure.
- enteric coating refers to any material that can protect an antigen from acidic degradation within the human stomach for a sufficiently long period of time such that at least ten percent of the antigen is delivered on average into the small intestines in an active form.
- enterric protective polymer refers to any polymer that protects an antigen from acidic degradation within the human stomach for a sufficiently long period of time such that at least ten percent of the antigen is delivered on average into the small intestines in an active form.
- encapsulate refers to any material that encapsulates another substance.
- water soluble polymer refers to a class of polymers for which more than ten percent of the mass of the polymer enters solution in a volume of water or aqueous fluid.
- pH sensitive polymer refers to a class of polymers that exhibit a pH dependent solubility profile.
- enzymes refers to a class of polymers containing regions that are chemically altered in the presence of one or more enzymes.
- zyme cleavable polymer refers to a class of polymers enzymatically degraded to yield a decrease in molecular weight.
- peptide refers to at least two of any amino acid or amino acid derivative linked by a peptide bond.
- the term “phlebotomy” refers to any means of obtaining a blood sample from a patient.
- net charge altering agent refers to any compound that alters the net charge of a solution or suspension temporarily or permanently.
- allergens for inducing tolerance can be utilized.
- peanut allergens including, but not limited to peanut flour, Arachis hypogaea 1 (Ara h1), Arachis hypogaea 1 (Ara h2); cat allergens, including but not limited to, Felis domesticus allergen 1-4 (Fel D1, Fel D2, Fel D3, Fel D4), and cat IgA; house dust mite allergens, including, but not limited to, Dermatophagoides pteronyssinus group 1 and 2 allergens (DER p1 and DER p2); other house dust allergens, for example, house dust endotoxin; pollen allergies, including, but not limited to Bet v and Bet v2; bee sting allergens, for example, phospholipase A2 (PLA2) one of the major bee venom allergen, wasp allergens; cockroach calyx, penicillin, sulfonamides, salicylates
- U.S. Pat. No. 8,182,805 to Viskari, et al. discloses enteroviruses useful for decreasing allergic sensitization, identified by their effect on regulatory T-cells and/or Th1/Th2-balance and/or production of immunoregulatory cytokines such as IL-10.
- the antigen is delivered in solution. In other embodiments, the antigen is delivered in suspension.
- the antigen is formulated such that at least seventy percent of the population of microparticles, more preferably at least eighty percent of the population, and most preferably at lest ninety percent of the population of microspheres is small enough to phagocytosed by macrophages or dendritic cells, and too large to be endocytosed in quantities sufficient to cause an untoward allergic response by other cell types.
- the microparticles of antigen are in an appropriate size range for macrophage engulfment, i.e., the microparticles have a mean equivalent circle diameter of between one and ten, more preferably between two and nine, and most preferably between three and six microns.
- the mean diameter of the population of microparticles in the case of irregularly shaped microparticles diameter refers to the diameter of a circle of equivalent cross-sectional area, is between two and nine microns, more preferably between three and eight microns, and most preferably between three and six microns.
- the at least seventy percent of, more preferably eighty percent of, and most preferably ninety percent of the diameter, or equivalent circle diameter, distribution within the population of administered antigen microspheres is within the range of one to ten microns, more preferably two to nine microns, and most preferably three to six microns.
- microparticles of antigen encapsulated in a polymer are administered orally as a reservoir-type or matrix-type delivery system.
- the microparticles are fabricated by one or a combination of the following techniques including, but not limited to, emulsion solvent evaporation, double emulsion solvent evaporation, ionic gelation, coacervation, membrane emulsification, supercritical fluid microencapsulation, spray drying, and hot melt microencapsulation.
- the antigen is microencapsulated within a water-soluble polymer, or combination thereof, for example, polyvinyl alcohol, methylcellulose, hydroxypropyl methylcellulose, starch, dextran, albumin, and sodium alginate.
- the antigen is microencapsulated in a pH-sensitive polymer that is stored at one pH and dissolves after entering the intradermal environment such as any of the following, or combination thereof, such as a polymer blend of acrylic acid and methacrylic acid, modified collagen, and modified crosslinked and un-crosslinked polyacrylic acids.
- the antigen is encapsulated in a biodegradable polymer, or combination thereof, such as a polyhydroxyacid like polylactic acid, polyglycolic acid, or polylactic-co-glycolic acid, polyanhydride, polyorthoester, polyphosphate ester, polycaprolactone, and polyglycerol sebacate.
- the antigen is encapsulated in a bioadhesive polymer, or combination thereof, such as polyfumaric-co-sebacic anhydride, chitosan, polyethylene maleic anhydride, catechol functional polymer, and lectin.
- the antigen is encapsulated in an enzymatically cleavable polymer that is sensitive to degradation by macrophage lysozomal enzymes.
- the enzymatically cleavable polymer contains peptide sequences cleaved by enzymes found in lysozomes, such as acid hydrolases and serine proteases.
- the antigen is encapsulated in hydrogel polymers such as calcium alginate, chitosan and chitosan derivative complexes (e.g. alginate-chitosan), polyethylene glycol, and poly-2-hydroxyethyl methacrylate.
- the antigen is microencapsulated in polyamino acids or combinations thereof such as polylysine, polyarginine, polyaspartate, and polyglutamate.
- the polymer microparticles containing antigen are administered within an enterically coated capsule or tablet.
- the polymer encapsulant is an enteric protective polymer such as one or a combination of the following including, but not limited to, Eudragit®L100, Eudragit®L100-55, Eudragit®S100, and modified collagen.
- the antigen is microencapsulated within a water-soluble polymer.
- the antigen is microencapsulated in a pH-sensitive polymer that is stored at one pH and dissolves after entering the intradermal environment such as any combination of the following including, but not limited to polymer blends of acrylic acid and methacrylic acid, modified collagen, and modified crosslinked and un-crosslinked polyacrylic acids.
- the antigen is encapsulated in a biodegradable polymer such as any combination of the following including, but not limited to, polylactic acid, polyglycolic acid, polylactic-co-glycolic acid, polyanhydrides, polyorthoesters, polyphosphate esters, polycaprolactone, and polyglycerol sebacate.
- the antigen is encapsulated in a bioadhesive polymer such as any combination of the following including, but not limited to polyfumaric-co-sebacic anhydride, chitosan, polyethylene maleic anhydride, catechol functional polymers, and lectins.
- the antigen is encapsulated in an enzymatically cleavable polymer that is sensitive to degradation by macrophage lysozomal enzymes.
- the enzymatically cleavable polymer contains peptide sequences cleaved by enzymes found in lysozomes, such as any combination of the following including, but not limited to acid hydrolases and serine proteases.
- release of the antigen from microcapsules can be accomplished using an encapsulating material that is specifically degraded by an enzyme or group of enzymes present within the phagocytic vesicles of a macrophage (e.g. phagosomes and phagolysosomes).
- the antigen containing microparticles exhibit degradation kinetics tailored to release antigen once the macrophages leave the systemic circulation on average and return to the lymph after injection, in some embodiments microparticles release less than twenty five percent of the antigen within two days after injection, more preferably less than fifteen percent of the antigen within two days after injection, and most preferably less than ten percent of the antigen within two days after injection.
- the encapsulating material can contain chitosan or a chitosan derivative (e.g. alginate-chitosan).
- Chitosan and chitosan-derivatives are substrates for degradation by lysozyme within the macrophage cell body. Lysozyme is present in highest concentrations within the phagolysosome, where the antigen would be released from microcapsules over time by degradation of the beta 1,4-beta-linkages along the backbone of the chitosan or chitosan-derivative polysaccharide after phagocytosis of microcapsules. These macrophages subsequently release some of the free antigen within the lymph.
- the antigen is encapsulated in hydrogel polymers such as any combination of the following including, but not limited to, calcium alginate, polyethylene glycol, and poly-2-hydroxyethyl methacrylate.
- the antigen is microencapsulated in polyamino acids.
- the antigen is encapsulated within more than one of the above polymers from a single or multiple groupings either physically mixed throughout each microparticle, or forming a core-shell morphology.
- the antigen is delivered along with an adjuvant excipients.
- the adjuvant is a net charge altering agent such as, but not limited to one or a combination of charged amino acids including lysine, arginine, histidine, glutamate, and aspartate.
- Uptake by macrophages can be encouraged by decorating the surface of the microcapsules with “scavenger receptors”, including, but not limited to, SR-AI and SR-AII or CD36, involved in triggering phagocytosis of apoptotic cells.
- scavenger receptors including, but not limited to, SR-AI and SR-AII or CD36, involved in triggering phagocytosis of apoptotic cells.
- functionalizing the microcapsule surface with an antibody, antibody derivative, antibody fragment, or aptamer to a macrophage surface protein, e.g. F4/80, Macrosialin (FA-11), Sialoadhesin (SER-4, 3D6), Mannose receptors, or Dectin-1 can be used to enhance phagocytotic uptake of microcapsules.
- the antigen is delivered along with an adjuvant.
- Adjuvants include, but are not limited to, highly charged polymers such as chitosan and polylysine.
- a net charge altering agent is incorporated into the allergen suspension or solution such as, but not limited to one or a combination of, charged amino acids including lysine, arginine, histidine, glutamate, and aspartate, to encourage macrophage engulfment.
- Individuals to be treated include any patient who suffers from sensitivity to an allergen.
- patients may suffer from any or a combination of food allergies, environmental allergies, dust mite allergy, insect bite or sting allergies, and pet allergies.
- any one or a combination of the above treatment modalities are administered to a patient once a month for three months, more preferably twice a month for three to six months, and most preferably every fourteen days for a period of forty-two days.
- the therapeutic regimen increases the immunoglobulin G levels within the patient, without significantly increasing the immunoglobulin E levels to induce allergen tolerance.
- the compositions improve allergic desensitization as measured by decreased Th2 response (for example, Th2-type cytokines) and/or increase Th1 responses, for example, Th1-type cytokines.
- the therapeutic regimen can reduce Th2 and/or increase Th1 responses.
- the treatment regimen increases Th1-response, for example, by increasing interferon gamma and/or interleukin 10 and/or 12 production.
- the treatment regimen can reduce Th2-type cytokines, for example interleukins 4, 5, and 13, which have been associated with the promotion of IgE and eosinophilic responses in atopy. Berger, BMJ, 321:424.1 (2000).
- compositions are utilized as appropriate for the specific route of administration.
- the formulation can be prepared in sterile saline, water or phosphate buffered saline.
- hydrogels or dry particles may be injected, implanted or inserted with microneedles.
- antigen is delivered by high-pressure intradermal injection through hollow microneedles.
- the high pressure is necessary to create a pocket in the dermis.
- High-pressure intradermal drug delivery is known in the art and described for example, in Gupta, et al., Biomateials, 32:6823-6831 (2011) and U.S. Publication No. 20090157041, the contents of which are hereby incorporated by reference.
- one or a plurality of solid microneedles is used to deliver the antigen intradermally.
- the antigen is formulated as a matrix-type or reservoir-type delivery system within a biodegradable polymer microstructure capable of penetrating the epidermis when supported by a biodegradable or non-degradable backing support layer.
- the tip radius of the microstructure is less than or approximately equal to twenty-five, more preferably ten, and most preferably five microns.
- the antigen is formulated as a matrix-type or reservoir-type delivery system within a biodegradable polymer microstructure capable of penetrating the epidermis when supported by a biodegradable or non-degradable backing support layer.
- the tip radius of the microstructure is less than or approximately equal to twenty-five, more preferably ten, and most preferably five microns.
- one or a combination of the following techniques such as micromolding, wet etching, dry etching, and laser cutting is used to fabricate the antigen into a biodegradable or water-soluble polymer in a sharp microstructure.
- the sharp biodegradable polymer microstructures are supported either by the same or a similar material, or a non-degradable support such as an array of metallic micropillar supports.
- a non-degradable support such as an array of metallic micropillar supports.
- Each individual microneedle is approximately two and one half, more preferably less than one and one half, and most preferably less than one millimeter in length.
- a portion of or the entire biodegradable or water-soluble component of the microneedle array containing the antigen remains within the dermis after removal of the backing.
- the biodegradable or water-soluble portions remaining in the dermis have an equivalent circle mean diameter of between one and ten, more preferably between two and nine, and most preferably between three and six microns.
- one or a combination of the following techniques such as micromolding, wet etching, dry etching, and laser cutting is used to fabricate the antigen into a biodegradable or water-soluble polymer in a sharp microstructure.
- the sharp biodegradable polymer microstructures are supported either by the same or a similar material, or a non-degradable support such as an array of metallic micropillar supports.
- a non-degradable support such as an array of metallic micropillar supports.
- Each individual microneedle is approximately two and one half, more preferably less than one and one half, and most preferably less than one millimeter in length.
- a portion of or the entire biodegradable or water-soluble component of the microneedle array containing the antigen remains within the dermis after removal of the backing.
- the biodegradable or water-soluble portions remaining in the dermis have an equivalent circle mean diameter of between one and ten, more preferably between two and nine, and most preferably between three and six microns.
- a net charge altering agent is incorporated into the allergen suspension or solution such as, but not limited to, one or a combination of charged amino acids, including lysine, arginine, histidine, glutamate, and aspartate, to encourage macrophage engulfment.
- microparticles of antigen are delivered orally in an enterically coated capsule or tablet.
- microparticles of antigen or polymer-encapsulated antigen are delivered to macrophages recruited from blood of the patient and then returned to the patient by injection or infusion.
- Whole blood is obtained from the patient by phlebotomy.
- the macrophages are separated from the whole blood by plating on tissue culture polystyrene or another material to which macrophages adhere.
- Microparticles of antigen or polymer-encapsulated antigen are introduced in suspension to the macrophages in an appropriate size range for phagocytosis. After a period of time sufficient for the macrophages to engulf a therapeutic quantity as part of an allergic desensitization regimen, the autologous macrophages are re-introduced into the patient by injection or intravenous infusion.
- a proposed mechanism is that macrophages, dendritic cells in the skin, and Peyer's patches in the ileum will transport the particles into the lymph, where the T and B cells can begin antibody production.
- a kit for this purpose could include heparinized vacuum collection tubes containing antigen encapsulated in particulate form, a heat block for incubation at physiological temperature (e.g. 37° C.), a syringe-coupled filter to separate the small, freely suspended microcapsules remaining after incubation from the blood, and a resuspension buffer for injection of the cells back into the patient.
- the heating element is a Peltier heating and cooling device; in another, the heating element is a resistive heater.
- the separation of macrophages from freely suspended antigen microparticles occurs by size exclusion. In another embodiment, the separation of macrophages from freely suspended antigen microparticles occurs based on differences in density between the microparticles and the macrophages.
- Low molecular weight chitosan greater than 75 percent deacetylated was dissolved in 1 percent aqueous glacial acetic acid to create a 5 milligram per milliliter aqueous chitosan solution.
- 9 milliliters of aqueous 1% ovalbumin, 0.1% sodium tripolyphosphate were added drop-wise into 18 milliliters of the 5 milligram per milliliter aqueous chitosan solution while vortexing.
- the resultant microparticles were sized by Coulter particle size analysis as shown in FIG. 1 .
- the resultant population is filtered through a 1 micron filter to produce microparticles suitable for allergic desensitization to ovalbumin.
Abstract
Description
- This application claims priority to U.S. Provisional Application No. 61/529,479 filed in the United States Patent and Trademark Office on Aug. 31, 2011, the disclosure of which is incorporated herein by reference.
- The present invention is generally in the field of compositions to induce tolerance to allergens.
- Fifty-five percent of people in the United States test positive to one or more allergens. According to the Asthma and Allergy Foundation, allergies are the fifth most common cause of chronic disease in the United States and third in children. Approximately ten million Americans are allergic to cat dander. Approximately seven percent of allergy sufferers have skin allergies, six percent have dietary allergies, and four percent have insect allergies as of 2007.
- Allergen immunotherapy, also known as allergy shots, is a form of long-term treatment that decreases symptoms for many people with allergic rhinitis, allergic asthma, conjunctivitis (eye allergy) or stinging insect allergy. Allergy shots decrease sensitivity to allergens and often lead to lasting relief of allergy symptoms even after treatment is stopped. This makes it a cost-effective, beneficial treatment approach for many people.
- Allergy shots work like a vaccine. The body responds to injected amounts of a particular allergen, given in gradually increasing doses, by developing immunity or tolerance to the allergen by producing immunoglobulin G (“IgG”) instead of IgE. Allergy shots are not used to treat food allergies. The best option for people with food allergies is to strictly avoid that food.
- There are two phases:
- Build-up phase. This involves receiving injections with increasing amounts of the allergens about one to two times per week. The length of this phase depends upon how often the injections are received, but generally ranges from three to six months.
- Maintenance phase. This begins once the effective dose is reached. The effective maintenance dose depends on the level of allergen sensitivity and the response to the build-up phase. During the maintenance phase, there will be longer periods of time between treatments, ranging from two to four weeks. Symptoms may decrease during the build-up phase, but it may take as long as 12 months on the maintenance dose to notice an improvement. If allergy shots are successful, maintenance treatment is generally continued for three to five years. Allergy shots have shown to decrease symptoms of many allergies. It can prevent the development of new allergies, and in children it can prevent the progression of allergic disease from allergic rhinitis to asthma. The effectiveness of allergy shots appears to be related to the length of the treatment program as well as the dose of the allergen. Some people experience lasting relief from allergy symptoms, while others may relapse after discontinuing allergy shots.
- Allergy is regarded as a Th2 weighted imbalance, and cytokines produced by Th2 lymphocytes, including
interleukins 4, 5, and 13, have been associated with the promotion of IgE and eosinophilic responses in atopy. Berger, BMJ, 321:424.1 (2000). Ways to redirect allergic Th2 responses in favor of Th1 responses should be beneficial in reducing incidences of allergic reactions. - In summary, better, and less invasive, means for inducing tolerance to allergens is needed. Rapid, effective desensitization to allergens is a significant unmet medical need that would alleviate a tremendous burden of chronic patient suffering.
- It is therefore an object of the present invention to provide methods and compositions to induce tolerance to allergens.
- Methods and compositions for delivering antigens to the lymphatic system in doses that desensitize patients to future exposure to antigens have been developed. Rapid desensitization is achieved by introducing small quantities of antigen into the lymphatic system. In preferred embodiments, the compositions provide therapeutically effective levels of antigen within the lymph, where macrophages reside in the greatest concentration. The compositions can be administered by intradermally, for example, via microneedles or microparticles, orally, for example, via enteric coated capsules or tablets, or by autologous transfusion.
- In some embodiments, the methods and compositions for delivering antigens orally achieve uptake by the Peyer's patches of the small intestine. In some embodiments, a population of macrophages exposed to antigen is isolated in whole or fractionated blood for autologous transfusion into the patient.
- In some embodiments compositions preferably increase immunoglobulin G levels specific to the allergen without significantly increasing the immunoglobulin E levels specific to the allergen. In other embodiments, the compositions improve allergic desensitization as measured by decreased Th2 response (for example, Th2-type cytokines) and/or increase Th1 responses, for example, Th1-type cytokines.
-
FIG. 1 shows Coulter particle sizing data of ovalbumin-chitosan microparticles for allergen desensitization. - As used herein, “rapid desensitization” refers to increasing the tolerance to one or a group of allergens more quickly than in the absence of treatment.
- As used herein, the term “tolerance” refers to the level of allergic response to a particular quantity of allergen.
- As used herein, the term “antigen” refers to a substance or substances alone or in combination that when introduced into the lymphatic system induces production of antibodies that bind to a fraction of the molecule or molecules.
- As used herein, the term “allergen” refers to a substance that could cause an allergic reaction in a patient.
- As used herein, the term “allergic reaction” refers to any untoward response to an allergen.
- As used herein, “lymphatic system” refers to the network of lymph containing vessels.
- As used herein, the term “intradermal” refers to residing within the dermal layer of skin or between the epidermal and dermal layers.
- As used herein, the term “microneedle” refers to a protrusion capable of penetrating the human epidermis in which its largest axis is less than three millimeters in length.
- As used herein, “sharp microneedle” refers to any microneedle that is capable of penetrating the human epidermis.
- As used herein, the term “microparticle” refers to any shaped particle that has at least one dimension less than one millimeter in size.
- As used herein, “autologous transfusion” refers to a whole or fractionated blood sample returned to the patient from whom it was taken by injection or intravenous infusion.
- As used herein, “equivalent circle diameter” refers to the diameter of a circle having the same cross-sectional area as the object being measured.
- As used herein, “reservoir-type delivery system” refers to formulations containing one or multiple antigen-rich and antigen-poor regions within each discrete element of the delivery system.
- As used herein, “matrix-type delivery system” refers to formulations containing a random distribution of antigen within each discrete element of the delivery system.
- As used herein, the term “biodegradable” refers to a class of materials that undergo reductions in molecular weight upon introduction into a cell-containing environment.
- As used herein, the term “bioadhesive” refers to a class of materials that adheres to one or more biological substrates.
- As used herein, the term “adjuvant” refers to any agent that increases the immunological response to an antigen.
- As used herein, the term “tip radius” refers to the radius of a circle equivalent in cross-sectional area to the smallest aspect of a microstructure.
- As used herein, the term “micropillar” refers to any microstructure that is longer than it is wide and mechanically supports another microstructure.
- As used herein, “enteric coating” refers to any material that can protect an antigen from acidic degradation within the human stomach for a sufficiently long period of time such that at least ten percent of the antigen is delivered on average into the small intestines in an active form. As used herein, “enteric protective polymer” refers to any polymer that protects an antigen from acidic degradation within the human stomach for a sufficiently long period of time such that at least ten percent of the antigen is delivered on average into the small intestines in an active form.
- As used herein, the term “encapsulate” refers to any material that encapsulates another substance.
- As used herein, “water soluble polymer” refers to a class of polymers for which more than ten percent of the mass of the polymer enters solution in a volume of water or aqueous fluid.
- As used herein, “pH sensitive polymer” refers to a class of polymers that exhibit a pH dependent solubility profile.
- As used herein, “enzymatically degradable polymer” refers to a class of polymers containing regions that are chemically altered in the presence of one or more enzymes.
- As used herein, “enzyme cleavable polymer” refers to a class of polymers enzymatically degraded to yield a decrease in molecular weight.
- As used herein, the term “peptide” refers to at least two of any amino acid or amino acid derivative linked by a peptide bond.
- As used herein, the term “phlebotomy” refers to any means of obtaining a blood sample from a patient.
- As used herein, the term “net charge altering agent” refers to any compound that alters the net charge of a solution or suspension temporarily or permanently.
- A. Allergens
- Clinically available allergens for inducing tolerance can be utilized. Examples include peanut allergens, including, but not limited to peanut flour, Arachis hypogaea 1 (Ara h1), Arachis hypogaea 1 (Ara h2); cat allergens, including but not limited to, Felis domesticus allergen 1-4 (Fel D1, Fel D2, Fel D3, Fel D4), and cat IgA; house dust mite allergens, including, but not limited to,
Dermatophagoides pteronyssinus group 1 and 2 allergens (DER p1 and DER p2); other house dust allergens, for example, house dust endotoxin; pollen allergies, including, but not limited to Bet v and Bet v2; bee sting allergens, for example, phospholipase A2 (PLA2) one of the major bee venom allergen, wasp allergens; cockroach calyx, penicillin, sulfonamides, salicylates, albumen, pollen, or their derivatives. U.S. Pat. No. 8,182,805 to Viskari, et al. discloses enteroviruses useful for decreasing allergic sensitization, identified by their effect on regulatory T-cells and/or Th1/Th2-balance and/or production of immunoregulatory cytokines such as IL-10. - B. Formulations
- In certain embodiments, the antigen is delivered in solution. In other embodiments, the antigen is delivered in suspension.
- Microparticles
- In those embodiments in which the antigen is delivered in suspension, the antigen is formulated such that at least seventy percent of the population of microparticles, more preferably at least eighty percent of the population, and most preferably at lest ninety percent of the population of microspheres is small enough to phagocytosed by macrophages or dendritic cells, and too large to be endocytosed in quantities sufficient to cause an untoward allergic response by other cell types. In specific embodiments, the microparticles of antigen are in an appropriate size range for macrophage engulfment, i.e., the microparticles have a mean equivalent circle diameter of between one and ten, more preferably between two and nine, and most preferably between three and six microns.
- In certain embodiments, the mean diameter of the population of microparticles, in the case of irregularly shaped microparticles diameter refers to the diameter of a circle of equivalent cross-sectional area, is between two and nine microns, more preferably between three and eight microns, and most preferably between three and six microns. In certain embodiments, the at least seventy percent of, more preferably eighty percent of, and most preferably ninety percent of the diameter, or equivalent circle diameter, distribution within the population of administered antigen microspheres is within the range of one to ten microns, more preferably two to nine microns, and most preferably three to six microns.
- In some embodiments, microparticles of antigen encapsulated in a polymer are administered orally as a reservoir-type or matrix-type delivery system. The microparticles are fabricated by one or a combination of the following techniques including, but not limited to, emulsion solvent evaporation, double emulsion solvent evaporation, ionic gelation, coacervation, membrane emulsification, supercritical fluid microencapsulation, spray drying, and hot melt microencapsulation.
- In some embodiments the antigen is microencapsulated within a water-soluble polymer, or combination thereof, for example, polyvinyl alcohol, methylcellulose, hydroxypropyl methylcellulose, starch, dextran, albumin, and sodium alginate. In some embodiments, the antigen is microencapsulated in a pH-sensitive polymer that is stored at one pH and dissolves after entering the intradermal environment such as any of the following, or combination thereof, such as a polymer blend of acrylic acid and methacrylic acid, modified collagen, and modified crosslinked and un-crosslinked polyacrylic acids. In some embodiments, the antigen is encapsulated in a biodegradable polymer, or combination thereof, such as a polyhydroxyacid like polylactic acid, polyglycolic acid, or polylactic-co-glycolic acid, polyanhydride, polyorthoester, polyphosphate ester, polycaprolactone, and polyglycerol sebacate. In some embodiments, the antigen is encapsulated in a bioadhesive polymer, or combination thereof, such as polyfumaric-co-sebacic anhydride, chitosan, polyethylene maleic anhydride, catechol functional polymer, and lectin. In some embodiments, the antigen is encapsulated in an enzymatically cleavable polymer that is sensitive to degradation by macrophage lysozomal enzymes. In some embodiments, the enzymatically cleavable polymer contains peptide sequences cleaved by enzymes found in lysozomes, such as acid hydrolases and serine proteases. In some embodiments, the antigen is encapsulated in hydrogel polymers such as calcium alginate, chitosan and chitosan derivative complexes (e.g. alginate-chitosan), polyethylene glycol, and poly-2-hydroxyethyl methacrylate. In some embodiments, the antigen is microencapsulated in polyamino acids or combinations thereof such as polylysine, polyarginine, polyaspartate, and polyglutamate.
- In some embodiments, the polymer microparticles containing antigen are administered within an enterically coated capsule or tablet. In some embodiments, the polymer encapsulant is an enteric protective polymer such as one or a combination of the following including, but not limited to, Eudragit®L100, Eudragit®L100-55, Eudragit®S100, and modified collagen. In some embodiments, the antigen is microencapsulated within a water-soluble polymer. In some embodiments, the antigen is microencapsulated in a pH-sensitive polymer that is stored at one pH and dissolves after entering the intradermal environment such as any combination of the following including, but not limited to polymer blends of acrylic acid and methacrylic acid, modified collagen, and modified crosslinked and un-crosslinked polyacrylic acids. In some embodiments, the antigen is encapsulated in a biodegradable polymer such as any combination of the following including, but not limited to, polylactic acid, polyglycolic acid, polylactic-co-glycolic acid, polyanhydrides, polyorthoesters, polyphosphate esters, polycaprolactone, and polyglycerol sebacate. In some embodiments, the antigen is encapsulated in a bioadhesive polymer such as any combination of the following including, but not limited to polyfumaric-co-sebacic anhydride, chitosan, polyethylene maleic anhydride, catechol functional polymers, and lectins. In some embodiments, the antigen is encapsulated in an enzymatically cleavable polymer that is sensitive to degradation by macrophage lysozomal enzymes. In some embodiments, the enzymatically cleavable polymer contains peptide sequences cleaved by enzymes found in lysozomes, such as any combination of the following including, but not limited to acid hydrolases and serine proteases.
- In some embodiments, release of the antigen from microcapsules can be accomplished using an encapsulating material that is specifically degraded by an enzyme or group of enzymes present within the phagocytic vesicles of a macrophage (e.g. phagosomes and phagolysosomes). In some embodiments, the antigen containing microparticles exhibit degradation kinetics tailored to release antigen once the macrophages leave the systemic circulation on average and return to the lymph after injection, in some embodiments microparticles release less than twenty five percent of the antigen within two days after injection, more preferably less than fifteen percent of the antigen within two days after injection, and most preferably less than ten percent of the antigen within two days after injection.
- In a specific embodiment, the encapsulating material can contain chitosan or a chitosan derivative (e.g. alginate-chitosan). Chitosan and chitosan-derivatives are substrates for degradation by lysozyme within the macrophage cell body. Lysozyme is present in highest concentrations within the phagolysosome, where the antigen would be released from microcapsules over time by degradation of the
beta 1,4-beta-linkages along the backbone of the chitosan or chitosan-derivative polysaccharide after phagocytosis of microcapsules. These macrophages subsequently release some of the free antigen within the lymph. - Hydrogels
- In some embodiments, the antigen is encapsulated in hydrogel polymers such as any combination of the following including, but not limited to, calcium alginate, polyethylene glycol, and poly-2-hydroxyethyl methacrylate. In some embodiments, the antigen is microencapsulated in polyamino acids. In some embodiments, the antigen is encapsulated within more than one of the above polymers from a single or multiple groupings either physically mixed throughout each microparticle, or forming a core-shell morphology. In some embodiments the antigen is delivered along with an adjuvant excipients. In some embodiments, the adjuvant is a net charge altering agent such as, but not limited to one or a combination of charged amino acids including lysine, arginine, histidine, glutamate, and aspartate.
- C. Adjuvants
- Uptake by macrophages can be encouraged by decorating the surface of the microcapsules with “scavenger receptors”, including, but not limited to, SR-AI and SR-AII or CD36, involved in triggering phagocytosis of apoptotic cells. In another embodiment, functionalizing the microcapsule surface with an antibody, antibody derivative, antibody fragment, or aptamer to a macrophage surface protein, e.g. F4/80, Macrosialin (FA-11), Sialoadhesin (SER-4, 3D6), Mannose receptors, or Dectin-1, can be used to enhance phagocytotic uptake of microcapsules.
- In some embodiments the antigen is delivered along with an adjuvant. Adjuvants include, but are not limited to, highly charged polymers such as chitosan and polylysine.
- In some embodiments, a net charge altering agent is incorporated into the allergen suspension or solution such as, but not limited to one or a combination of, charged amino acids including lysine, arginine, histidine, glutamate, and aspartate, to encourage macrophage engulfment.
- A. Individuals to be Treated and Treatment Regime
- Patients to be Treated
- Individuals to be treated include any patient who suffers from sensitivity to an allergen. In specific embodiments patients may suffer from any or a combination of food allergies, environmental allergies, dust mite allergy, insect bite or sting allergies, and pet allergies.
- Therapeutic Regimen
- Any one or a combination of the above treatment modalities are administered to a patient once a month for three months, more preferably twice a month for three to six months, and most preferably every fourteen days for a period of forty-two days. In some embodiments, the therapeutic regimen increases the immunoglobulin G levels within the patient, without significantly increasing the immunoglobulin E levels to induce allergen tolerance. In other embodiments, the compositions improve allergic desensitization as measured by decreased Th2 response (for example, Th2-type cytokines) and/or increase Th1 responses, for example, Th1-type cytokines. For example, the therapeutic regimen can reduce Th2 and/or increase Th1 responses. In these embodiments, the treatment regimen increases Th1-response, for example, by increasing interferon gamma and/or
interleukin 10 and/or 12 production. Gerada, et al., Lancet, 13:355(9216):1680-3 (2000). The treatment regimen can reduce Th2-type cytokines, forexample interleukins 4, 5, and 13, which have been associated with the promotion of IgE and eosinophilic responses in atopy. Berger, BMJ, 321:424.1 (2000). - B. Routes of Administration
- Pharmaceutically acceptable excipients are utilized as appropriate for the specific route of administration. For example, for injection, the formulation can be prepared in sterile saline, water or phosphate buffered saline. Alternatively, hydrogels or dry particles may be injected, implanted or inserted with microneedles.
- Intradermal Delivery using Microneedles
- In a preferred embodiment, antigen is delivered by high-pressure intradermal injection through hollow microneedles. The high pressure is necessary to create a pocket in the dermis. High-pressure intradermal drug delivery is known in the art and described for example, in Gupta, et al., Biomateials, 32:6823-6831 (2011) and U.S. Publication No. 20090157041, the contents of which are hereby incorporated by reference. In some embodiments, one or a plurality of solid microneedles is used to deliver the antigen intradermally. In these embodiments, the antigen is formulated as a matrix-type or reservoir-type delivery system within a biodegradable polymer microstructure capable of penetrating the epidermis when supported by a biodegradable or non-degradable backing support layer. To achieve epidermal penetration at minimal force, the tip radius of the microstructure is less than or approximately equal to twenty-five, more preferably ten, and most preferably five microns.
- In these embodiments, the antigen is formulated as a matrix-type or reservoir-type delivery system within a biodegradable polymer microstructure capable of penetrating the epidermis when supported by a biodegradable or non-degradable backing support layer. To achieve epidermal penetration at minimal force, the tip radius of the microstructure is less than or approximately equal to twenty-five, more preferably ten, and most preferably five microns.
- In specific embodiments, one or a combination of the following techniques such as micromolding, wet etching, dry etching, and laser cutting is used to fabricate the antigen into a biodegradable or water-soluble polymer in a sharp microstructure. The sharp biodegradable polymer microstructures are supported either by the same or a similar material, or a non-degradable support such as an array of metallic micropillar supports. When the device is placed into the skin, it penetrates the epidermis and contacts or enters the dermis. Each individual microneedle is approximately two and one half, more preferably less than one and one half, and most preferably less than one millimeter in length. In certain embodiments, a portion of or the entire biodegradable or water-soluble component of the microneedle array containing the antigen remains within the dermis after removal of the backing.
- To encourage phagocytosis by macrophages and dendritic cells, the biodegradable or water-soluble portions remaining in the dermis have an equivalent circle mean diameter of between one and ten, more preferably between two and nine, and most preferably between three and six microns.
- In specific embodiments, one or a combination of the following techniques such as micromolding, wet etching, dry etching, and laser cutting is used to fabricate the antigen into a biodegradable or water-soluble polymer in a sharp microstructure. The sharp biodegradable polymer microstructures are supported either by the same or a similar material, or a non-degradable support such as an array of metallic micropillar supports. When the device is placed into the skin, it penetrates the epidermis and contacts or enters the dermis. Each individual microneedle is approximately two and one half, more preferably less than one and one half, and most preferably less than one millimeter in length. In certain embodiments, a portion of or the entire biodegradable or water-soluble component of the microneedle array containing the antigen remains within the dermis after removal of the backing.
- To encourage phagocytosis by macrophages and dendritic cells, the biodegradable or water-soluble portions remaining in the dermis have an equivalent circle mean diameter of between one and ten, more preferably between two and nine, and most preferably between three and six microns. In some embodiments, a net charge altering agent is incorporated into the allergen suspension or solution such as, but not limited to, one or a combination of charged amino acids, including lysine, arginine, histidine, glutamate, and aspartate, to encourage macrophage engulfment.
- Oral Delivery
- In some embodiments, microparticles of antigen are delivered orally in an enterically coated capsule or tablet.
- Autologous Infusion Therapy
- In some embodiments, microparticles of antigen or polymer-encapsulated antigen are delivered to macrophages recruited from blood of the patient and then returned to the patient by injection or infusion. Whole blood is obtained from the patient by phlebotomy. In some embodiments, the macrophages are separated from the whole blood by plating on tissue culture polystyrene or another material to which macrophages adhere. Microparticles of antigen or polymer-encapsulated antigen are introduced in suspension to the macrophages in an appropriate size range for phagocytosis. After a period of time sufficient for the macrophages to engulf a therapeutic quantity as part of an allergic desensitization regimen, the autologous macrophages are re-introduced into the patient by injection or intravenous infusion.
- A proposed mechanism is that macrophages, dendritic cells in the skin, and Peyer's patches in the ileum will transport the particles into the lymph, where the T and B cells can begin antibody production.
- A kit for this purpose could include heparinized vacuum collection tubes containing antigen encapsulated in particulate form, a heat block for incubation at physiological temperature (e.g. 37° C.), a syringe-coupled filter to separate the small, freely suspended microcapsules remaining after incubation from the blood, and a resuspension buffer for injection of the cells back into the patient. In one embodiment, the heating element is a Peltier heating and cooling device; in another, the heating element is a resistive heater. In one embodiment, the separation of macrophages from freely suspended antigen microparticles occurs by size exclusion. In another embodiment, the separation of macrophages from freely suspended antigen microparticles occurs based on differences in density between the microparticles and the macrophages.
- The present invention will be further understood by the following non-limiting examples.
- Low molecular weight chitosan greater than 75 percent deacetylated was dissolved in 1 percent aqueous glacial acetic acid to create a 5 milligram per milliliter aqueous chitosan solution. 9 milliliters of aqueous 1% ovalbumin, 0.1% sodium tripolyphosphate were added drop-wise into 18 milliliters of the 5 milligram per milliliter aqueous chitosan solution while vortexing.
- The resultant microparticles were sized by Coulter particle size analysis as shown in
FIG. 1 . To isolate the population of microparticles that are approximately 2 microns in apparent diameter, the resultant population is filtered through a 1 micron filter to produce microparticles suitable for allergic desensitization to ovalbumin. - Modifications and variations of the present invention will be obvious from the foregoing description and are intended to come within the scope of the following claims.
Claims (22)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/240,706 US20140207105A1 (en) | 2011-08-31 | 2012-08-30 | Methods for Effectively and Rapidly Desensitizing Allergic Patients |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161529479P | 2011-08-31 | 2011-08-31 | |
US14/240,706 US20140207105A1 (en) | 2011-08-31 | 2012-08-30 | Methods for Effectively and Rapidly Desensitizing Allergic Patients |
PCT/US2012/053145 WO2013033400A2 (en) | 2011-08-31 | 2012-08-30 | Methods for effectively and rapidly desensitizing allergic patients |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/053145 A-371-Of-International WO2013033400A2 (en) | 2011-08-31 | 2012-08-30 | Methods for effectively and rapidly desensitizing allergic patients |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/480,564 Continuation US10092641B2 (en) | 2011-08-31 | 2017-04-06 | Methods for effectively and rapidly desensitizing allergic patients |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140207105A1 true US20140207105A1 (en) | 2014-07-24 |
Family
ID=47757171
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/240,706 Abandoned US20140207105A1 (en) | 2011-08-31 | 2012-08-30 | Methods for Effectively and Rapidly Desensitizing Allergic Patients |
US15/480,564 Active US10092641B2 (en) | 2011-08-31 | 2017-04-06 | Methods for effectively and rapidly desensitizing allergic patients |
US16/144,450 Abandoned US20200129616A1 (en) | 2011-08-31 | 2018-09-27 | Methods for effectively and rapidly desensitizing allergic patients |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/480,564 Active US10092641B2 (en) | 2011-08-31 | 2017-04-06 | Methods for effectively and rapidly desensitizing allergic patients |
US16/144,450 Abandoned US20200129616A1 (en) | 2011-08-31 | 2018-09-27 | Methods for effectively and rapidly desensitizing allergic patients |
Country Status (8)
Country | Link |
---|---|
US (3) | US20140207105A1 (en) |
EP (1) | EP2750705B1 (en) |
JP (1) | JP2014525458A (en) |
AU (2) | AU2012301814A1 (en) |
CA (1) | CA2846858C (en) |
DK (1) | DK2750705T3 (en) |
ES (1) | ES2936312T3 (en) |
WO (1) | WO2013033400A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140271836A1 (en) * | 2013-03-14 | 2014-09-18 | Allergen Research Corporation | Manufacture of peanut formulations for oral desensitization |
US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
US20190183405A1 (en) * | 2016-08-12 | 2019-06-20 | Industry-Academic Cooperation Foundation, Yonsei University | Micro-needle patch, method for manufacturing the micro-needle patch, and method for diagnosing allergy disease using the micro-needle patch |
US11229673B2 (en) | 2019-05-10 | 2022-01-25 | Société des Produits Nestlé S.A. | Methods for improving the quality of life of a patient with a peanut allergy |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8834423B2 (en) | 2009-10-23 | 2014-09-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Dissolvable microneedle arrays for transdermal delivery to human skin |
CA2846858C (en) * | 2011-08-31 | 2022-03-08 | Perosphere, Inc. | Methods for effectively and rapidly desensitizing allergic patients |
US10441768B2 (en) | 2015-03-18 | 2019-10-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioactive components conjugated to substrates of microneedle arrays |
US11684763B2 (en) | 2015-10-16 | 2023-06-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices |
WO2017120322A1 (en) * | 2016-01-05 | 2017-07-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Skin microenvironment targeted delivery for promoting immune and other responses |
RS62442B1 (en) | 2016-03-15 | 2021-11-30 | Igor Polyakov | Compositions for the treatment and prevention of hoof and claw diseases |
HUE054207T2 (en) * | 2016-03-15 | 2021-08-30 | Igor Polyakov | New immunobiological products |
US11318199B2 (en) | 2017-05-31 | 2022-05-03 | Texas Tech University System | Methods and devices for the treatment of food allergies |
WO2023064610A2 (en) * | 2021-10-14 | 2023-04-20 | Georgia Tech Research Corporation | Systems and methods for angled insertion of microneedles for targeted delivery |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811128A (en) * | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US6611707B1 (en) * | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
US20050095298A1 (en) * | 2002-04-22 | 2005-05-05 | Hans Gronlund | Microparticles comprising carbohydrate beads covalently linked with allergen |
US20080269666A1 (en) * | 2005-05-25 | 2008-10-30 | Georgia Tech Research Corporation | Microneedles and Methods for Microinfusion |
US7473247B2 (en) * | 1999-10-14 | 2009-01-06 | Becton, Dickinson And Company | Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
US7611481B2 (en) * | 2004-03-24 | 2009-11-03 | Corium International, Inc. | Transdermal delivery device |
US20100151000A1 (en) * | 2006-10-12 | 2010-06-17 | The University Of Queensland | Compositions and methods for modulating immune responses |
US7942827B2 (en) * | 2005-07-11 | 2011-05-17 | Infotonics Technology Center, Inc. | Minimally invasive allergy testing system |
US8540672B2 (en) * | 2010-12-22 | 2013-09-24 | Valeritas, Inc. | Microneedle patch applicator |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1055465A (en) * | 1962-09-27 | 1967-01-18 | Vantorex Ltd | Allergenic aerosol compositions |
US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
US6410723B1 (en) | 2000-07-24 | 2002-06-25 | Imclone Systems Incorporated | VDUP1 promoter and methods of use thereof |
US6773695B2 (en) * | 2000-10-05 | 2004-08-10 | Mannkind Corporation | Modulation of allergic response |
AU2002252073A1 (en) * | 2001-02-22 | 2002-09-12 | The Scepens Eye Research Institute, Inc. | Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions |
DK1432466T3 (en) | 2001-09-12 | 2012-12-03 | Becton Dickinson Co | Micro needle-based pen dispenser for drug delivery and method of use thereof |
WO2004019978A1 (en) * | 2002-08-29 | 2004-03-11 | National University Of Singapore | Recombinant nucleic acid useful for inducing protective immune response against allergens |
JP5006196B2 (en) | 2005-08-01 | 2012-08-22 | 久光製薬株式会社 | Adjuvants and formulations for transdermal or transmucosal administration |
EP1956985A2 (en) | 2005-11-23 | 2008-08-20 | Universität Zürich | Allergy treatment by epicutaneous allergen administration |
WO2008054892A2 (en) * | 2006-06-16 | 2008-05-08 | Florida Atlantic University | Chitin micro-particles as an adjuvant |
TR201807756T4 (en) * | 2006-09-26 | 2018-06-21 | Infectious Disease Res Inst | Vaccine composition containing synthetic adjuvant. |
JP2010511417A (en) * | 2006-10-30 | 2010-04-15 | シーエムピー セラピューティクス リミテッド | Method for producing fine particles |
CA2667637C (en) * | 2006-10-31 | 2021-04-20 | East Carolina University | Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders |
FI20075063A0 (en) | 2007-02-01 | 2007-02-01 | Vactech Oy | Prevention of allergic sensitization |
FR2924349B1 (en) | 2007-12-03 | 2010-01-01 | Dbv Tech | ALLERGEN DISENSIBILITY METHOD |
US20100278880A1 (en) * | 2008-01-02 | 2010-11-04 | Biotech Tools S.A. | Pharmaceutical formulation for allergen preparation |
EP2123261A1 (en) | 2008-05-20 | 2009-11-25 | Stallergenes S.A. | Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance |
JP5491119B2 (en) * | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | Pharmaceutical composition containing drug-containing microparticles and method for producing the same |
CA2846858C (en) * | 2011-08-31 | 2022-03-08 | Perosphere, Inc. | Methods for effectively and rapidly desensitizing allergic patients |
-
2012
- 2012-08-30 CA CA2846858A patent/CA2846858C/en active Active
- 2012-08-30 US US14/240,706 patent/US20140207105A1/en not_active Abandoned
- 2012-08-30 ES ES12828090T patent/ES2936312T3/en active Active
- 2012-08-30 DK DK12828090.6T patent/DK2750705T3/en active
- 2012-08-30 JP JP2014528602A patent/JP2014525458A/en active Pending
- 2012-08-30 WO PCT/US2012/053145 patent/WO2013033400A2/en active Application Filing
- 2012-08-30 AU AU2012301814A patent/AU2012301814A1/en not_active Abandoned
- 2012-08-30 EP EP12828090.6A patent/EP2750705B1/en active Active
-
2017
- 2017-04-06 US US15/480,564 patent/US10092641B2/en active Active
-
2018
- 2018-02-09 AU AU2018200963A patent/AU2018200963B2/en active Active
- 2018-09-27 US US16/144,450 patent/US20200129616A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811128A (en) * | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US6611707B1 (en) * | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
US7473247B2 (en) * | 1999-10-14 | 2009-01-06 | Becton, Dickinson And Company | Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
US20050095298A1 (en) * | 2002-04-22 | 2005-05-05 | Hans Gronlund | Microparticles comprising carbohydrate beads covalently linked with allergen |
US7611481B2 (en) * | 2004-03-24 | 2009-11-03 | Corium International, Inc. | Transdermal delivery device |
US20080269666A1 (en) * | 2005-05-25 | 2008-10-30 | Georgia Tech Research Corporation | Microneedles and Methods for Microinfusion |
US7942827B2 (en) * | 2005-07-11 | 2011-05-17 | Infotonics Technology Center, Inc. | Minimally invasive allergy testing system |
US20100151000A1 (en) * | 2006-10-12 | 2010-06-17 | The University Of Queensland | Compositions and methods for modulating immune responses |
US8540672B2 (en) * | 2010-12-22 | 2013-09-24 | Valeritas, Inc. | Microneedle patch applicator |
Non-Patent Citations (4)
Title |
---|
Bjorksten et al. 'Clinical and immunological efects of oral immunotherapy with a standardized birch pollen extract.' Allergy. 41:290-295, 1986. * |
Blumenthal et al. 'Definition of an allergen.' Allergens and Allergen Immunotherapy. Ed. R. Lockey et al. New York: Marcel Decker, 2004.37-50. * |
Mitragotri et al. 'Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.' Nature Rev. 13:655-672, 2014. * |
Secrist et al., J. Exp. Med. 178:2123, 1993. * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140271836A1 (en) * | 2013-03-14 | 2014-09-18 | Allergen Research Corporation | Manufacture of peanut formulations for oral desensitization |
US9198869B2 (en) * | 2013-03-14 | 2015-12-01 | Aimmune Therapeutics, Inc. | Manufacture of peanut formulations for oral desensitization |
US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
US10086068B2 (en) | 2013-03-14 | 2018-10-02 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
US10449118B2 (en) | 2013-03-14 | 2019-10-22 | Aimmune Therapeutics, Inc. | Manufacture of peanut formulations for oral desensitization |
US10512686B2 (en) | 2013-03-14 | 2019-12-24 | Aimmune Therapeutics, Inc. | Peanut formulations and used thereof |
US20200129378A1 (en) * | 2013-03-14 | 2020-04-30 | Aimmune Therapeutics, Inc. | Manufacture of peanut formulations for oral desensitization |
US10653773B2 (en) | 2013-03-14 | 2020-05-19 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
US11141352B2 (en) * | 2013-03-14 | 2021-10-12 | Société des Produit Nestlé S.A. | Manufacture of peanut formulations for oral desensitization |
US20190183405A1 (en) * | 2016-08-12 | 2019-06-20 | Industry-Academic Cooperation Foundation, Yonsei University | Micro-needle patch, method for manufacturing the micro-needle patch, and method for diagnosing allergy disease using the micro-needle patch |
US11229673B2 (en) | 2019-05-10 | 2022-01-25 | Société des Produits Nestlé S.A. | Methods for improving the quality of life of a patient with a peanut allergy |
Also Published As
Publication number | Publication date |
---|---|
WO2013033400A9 (en) | 2013-05-16 |
WO2013033400A2 (en) | 2013-03-07 |
ES2936312T3 (en) | 2023-03-16 |
AU2018200963A1 (en) | 2018-03-01 |
AU2018200963B2 (en) | 2020-02-27 |
US20200129616A1 (en) | 2020-04-30 |
CA2846858C (en) | 2022-03-08 |
EP2750705B1 (en) | 2022-11-16 |
AU2012301814A1 (en) | 2014-02-27 |
EP2750705A2 (en) | 2014-07-09 |
DK2750705T3 (en) | 2023-01-23 |
EP2750705A4 (en) | 2015-09-02 |
JP2014525458A (en) | 2014-09-29 |
US20170209567A1 (en) | 2017-07-27 |
US10092641B2 (en) | 2018-10-09 |
CA2846858A1 (en) | 2013-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018200963B2 (en) | Methods for effectively and rapidly desensitizing allergic patients | |
Pohlit et al. | Recent advances in the use of nanoparticles for allergen‐specific immunotherapy | |
Mittal et al. | Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization | |
EP2464341B1 (en) | Immunomodulatory compositions comprising a polymer matrix and an oil phase | |
Li et al. | Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers | |
AU2013285353B2 (en) | Hydrogel vaccine formulations | |
Bennewitz et al. | The effect of the physical form of poly (lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen | |
JP2014525458A5 (en) | ||
US20050123596A1 (en) | pH-triggered microparticles | |
US20010031262A1 (en) | Controlled delivery of antigens | |
JPH05503285A (en) | Glucan delivery system and complementary drugs | |
De Temmerman et al. | Polyelectrolyte LbL microcapsules versus PLGA microparticles for immunization with a protein antigen | |
PT1322330E (en) | Modulation of allergic response | |
Chen et al. | Development of Yersinia pestis F1 antigen-loaded liposome vaccine against plague using microneedles as a delivery system | |
Nesovic et al. | Treating allergies via skin–recent advances in cutaneous allergen immunotherapy | |
CN101502649B (en) | Liposome influenza vaccine | |
Kohane et al. | pH-triggered release of macromolecules from spray-dried polymethacrylate microparticles | |
US20190060426A1 (en) | Method and apparatus for microneedle transdermal delivery | |
AU2005244128B2 (en) | Pulmonary malarial vaccine | |
CN113181354A (en) | Foot-and-mouth disease bionic nano vaccine based on dendritic cells and preparation method and application thereof | |
WO2011138050A1 (en) | Method for vaccination | |
WO2015056710A1 (en) | Transdermal immune preparation | |
Alouffi et al. | Advancement in the Development of DNA Vaccines Against Trypanosoma brucei and Future Perspective | |
孔慶靚 | Development of allerge-nspecific immunotherapy of Japanese cedar pollinosis using solid-in-oil nanodispersions | |
Cortesi et al. | Pharmaceutical and biotechnological applications of multiple emulsions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PEROSPHERE INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LAULICHT, BRYAN E.;STEINER, SOLOMON S.;BAKHRU, SASHA H.;AND OTHERS;SIGNING DATES FROM 20121019 TO 20130603;REEL/FRAME:030613/0606 |
|
AS | Assignment |
Owner name: PEROSPHERE TECHNOLOGIES INC., CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PEROSPHERE PHARMACEUTICALS INC.;REEL/FRAME:043805/0031 Effective date: 20170929 Owner name: PEROSPHERE PHARMACEUTICALS INC., CONNECTICUT Free format text: CHANGE OF NAME;ASSIGNOR:PEROSPHERE INC.;REEL/FRAME:044144/0970 Effective date: 20170929 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: PEROSPHERE TECHNOLOGIES INC., CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PEROSPHERE PHARMACEUTICALS INC.;REEL/FRAME:046469/0588 Effective date: 20170929 |